http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8071580-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24de8e23be1083abd94e7ba2ee4f1ff2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1111151fe0abdd3d1e1ca0bd2934c13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fc538aabc029bbeb14fa27cae4d5594 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_534bf8414675a4df1f3609910d91563e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-045 |
| filingDate | 2005-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3bc87124f0d0e8e6001b6ad968add36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a166ce1c2bc7aad73c66a393d4d4297 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dffa525585dc9df1da63af838f2c7ea |
| publicationDate | 2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8071580-B2 |
| titleOfInvention | Medium-chain length fatty alcohols as stimulators of hematopoiesis |
| abstract | Medium-chain length fatty alcohols such as octanol, decanol, dodecanol, or analogues thereof can be used as a stimulator of hematopoiesis, hematopoietic stem cell proliferation, and/or proliferation of one or more of the progenitors of red or white blood cells (e.g., erythrocyte, leukocyte, neutrophil, granulocyte, megakaryocyte, or any combination thereof). It also relates to the treatment of myelosuppression; in particular, this includes the treatment of anemia and/or neutropenia associated with chemotherapy and/or radiotherapy. Moreover, anemia arising from chronic renal failure or treatment of HIV-infected patients with AZT (zidovudine), or other inhibitors of reverse transcriptase, can be treated. Furthermore, neutropenia arising from infections, hematologic diseases, or nutritional deficiencies can be treated. It also relates to reducing drug toxicity and enhancing drug efficiency. |
| priorityDate | 2004-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.